Taken together, our study demonstrate that VPAC1 is significantly overexpressed in gastric cancer and VPAC1/TRPV4/Ca 2+ signaling axis could enforce a positive feedback regulation in gastric cancer progression. VIP/VPAC1 may serve as potential prognostic markers and therapeutic targets for gastric cancer.
Introduction
Gastric cancer (GC) is the second leading cause of cancer-related death worldwide (Siegel RL et al, 2016) . Despite important advances in the understanding of pathology and molecular mechanisms, the prognosis of GC remains poor due to the early invasion and metastasis (Tan P & Yeoh KG, 2015; Badgwell B et al, 2016) . Currently, there are no specific molecular signatures of gastric cancer metastasis and progression. Thus, it is urgent to explore novel diagnostic markers and mechanisms responsible for the development and progression of GC.
VPAC1, a member of the G-protein-coupled receptor (GPCR) superfamily, is mainly activated by vasoactive intestinal peptide (VIP), a ligand of VPAC1 that belongs to the pituitary adenylyl cyclase-activating polypeptide family . Aberrant expression of VPAC1 is implicated in several human diseases, such as autoimmune disease, neurological disease and carcinogenesis (Seoane IV et al, 2016; White CM et al, 2010; Valdehita A et al, 2009; (Valdehita A et al, 2007) . The role of VPAC1 and VIP in tumor progression has been gradually recognized, and they are frequently overexpressed in a variety of malignancies (Reubi JC et al, 2000; Fernández-Martínez AB et al, 2012; Liu S et al, 2014) . However, the role of VPAC1 in gastric cancer progression remains unknown. VPAC1 activation induces not only an increase in intracellular cAMP in many types of cells, but also a rise in cytoplasmic free Ca 2+ ([Ca 2+ ] cyt ) (Dickson L et al, 2009; Zhang S et al, 2010; Herrera JL et al, 2009) . [Ca 2+ ] cyt elevation is a mechanism well suited to the rapid transmission of signals from tumor microenvironment into cellular responses (Berridge MJ et al, 2003; Monteith GR et al, 2012) , and an ubiquitous mechanism that controls cell survival, proliferation, motility, differentiation, and cancer progression (Fiorio Pla A et al, 2012; Wei C et al, 2009) . (Berridge MJ et al, 2003; Evans AM et al, 2016) . A major determinant of these is the participation of distinct Ca 2+ -permeable channels (Hofer AM & Brown EM, 2003; Déliot N & Constantin B, 2015) , among which transient receptor potential vanilloid 4 (TRPV4), a member of the transient receptor potential (TRP) superfamily, is able to regulate a variety of Ca
2+
-dependent cellular functions in gastrointestinal tract (Holzer P, 2011; D'Aldebert E et al, 2011) . However, except for a few studies to address its involvement in inflammatory bowel diseases (Holzer P, 2011; D'Aldebert E et al, 2011) , nothing is currently known about the pathological role of TRPV4 in gastrointestinal cancers.
In the present study, we demonstrate for the first time an overexpression of VPAC1 in human gastric cancer, which is closely correlated with advanced clinicopathological features and poor survival of gastric cancer patients. We also reveal that VPAC1 activation promotes migration and invasion of GC cells through TRPV4 channel-dependent Ca 2+ entry, which in turn augments VIP expression and secretion to drive several downstream signaling cascades to promote GC progression. Enhanced expressions of VPAC1 have potentially diagnostic and prognostic significance for gastric cancer, and targeted inhibition of VPAC1 expression and its downstream signaling could attenuate metastasis of gastric cancer, which may be a novel candidate for gastric cancer diagnosis and therapy.
Results
Enhanced expression of VIP and VPAC1 in primary gastric cancer correlates with metastasis and poor prognosis 6 We first measured the expression level of VPAC1 in gastric cancer cell lines, normal gastric epithelial cell GES-1 and gastric cancer tissues. As shown in Appendix Fig S1A and B, both mRNA and protein expression levels of VPAC1 were much higher in gastric cancer cells than in normal gastric GES-1 cells. Consistently, VPAC1 was significantly upregulated in gastric cancer tissues compared with their matched adjacent non-tumor tissues (Appendix Fig S1C and D) . We further examined the expression of VIP and VPAC1 in biopsy samples from 238 GC patients using immunohistochemistry (Fig 1A) . Semi-quantitative analysis showed an obvious upregulation of VIP and VPAC1 expression in GC tissues compared with adjacent non-tumor tissues ( Fig 1B and C) . Furthermore, VIP and VPAC1 were expressed at higher levels in the metastasis-positive group than those in the non-metastasis group (P<0.001) and were related to advanced TNM stage (P<0.0001) (Fig 1D and E) . We further evaluated the correlation between VIP/VAPC1 levels and patient clinicopathological characteristics, and found that high expression of VIP and VPAC1 was significantly associated with deeper tumor invasion, lymph node metastasis, advanced tumor stage and distant metastasis (Appendix Table S1 ). Additionally, Kaplan-Meier survival analysis showed that the high expression of VIP and VPAC1 strongly correlated with a decreased survival time (P<0.0001) (Fig 1F and G) , consistent with the results extracted from KM Plotter database (Appendix Fig S2) . Notably, short survival was observed in the group with high expression of both VIP and VPAC1, but long survival in the group with low expression of both proteins (Fig 1H) . To further explore the role of VPAC1 and VIP in predicting gastric cancer prognosis, we performed univariate and multivariate analyses of clinical follow-up data. We found that deeper tumor invasion, lymph node metastasis, advanced tumor stage, distant metastasis and higher expression of VIP and VPAC1 were significantly associated with poorer survival on univariable analysis (Appendix Table S2 Table S2 ). Taken together, these data indicated that VIP/VPAC1 significantly contribute to gastric cancer metastasis and progression, implicating them as potential prognostic biomarker in gastric cancer.
VIP enhances migration and invasion of gastric cancer cells in vitro and metastasis in vivo through activation of VPAC1
We found that VIP enhanced the migration and invasion of GC cells, which was attenuated by knockdown of VPAC1 (Fig 2A and B and Appendix Fig S3A and B) . Furthermore, VIP significantly increased the lung metastasis and peritoneal dissemination, while VPAC1 knockdown markedly attenuated the effect of VIP (Fig 2C and D) . Our immunohistochemistry and western blot analysis confirmed the effective knockdown of VPAC1 in the tumor nodules (Appendix Fig S4A and B) . Taken together, these results strongly suggest that VIP promotes the migration, invasion and metastasis of GC through VPAC1.
VPAC1 activation induces Ca 2+ signaling to promote migration and invasion of gastric cancer cells
VPAC1 is also coupled to phospholipase Cβ (PLCβ) and Ca 2+ signaling that is critical for the migration and invasion of cancer cells (Chen YF et al, 2013 . Indeed, VIP induced [Ca 2+ ] cyt increases in MKN45 cells in a concentration-dependent manner (Fig 3A) , which was abolished by VPAC1 knockdown (Fig 3B and Appendix Fig S5A and ] cyt rise only in VPAC1-expressing HEK293 cells (Fig 3C) .
Moreover, U73122, a PLC inhibitor, significantly attenuated the VIP-induced [Ca 2+ ] cyt rise ( Fig   3D) . Finally, BAPTA-AM, a [Ca 2+ ] cyt chelator, significantly attenuated VIP-induced migration and invasion of GC cells (Appendix Fig S6A-F ] cyt rise was attenuated by the pretreatment with 2-aminoethoxydiphenyl borate (2-APB, 100 µM) ( Fig 3G and Appendix Fig S5D) , a nonspecific inhibitor of TRP channels, suggesting their possible involvements in VIP-induced Ca 2+ entry. Fig S7B and C) , which was strongly attenuated by RN1734 ( Fig 4E and Appendix Fig S7D) and the knockdown of TRPV4 expression (Fig 4F) . VIP also evoked outwardly rectifying currents in MKN45 cells (Fig 4G) , and to a lesser extent in GES-1 cells (Fig 4H) , which were both inhibited by RN1734, confirming that VAPC1 activation by VIP induces Ca 2+ entry through TRPV4 channels.
VPAC1 activation induces

VPAC1 activation induces Ca 2+ entry via TRPV4 channels in a DAG-dependent manner
To elucidate the detail mechanisms by which VIP/VPAC1 activates TRPV4 channels, we first tested if VIP/VPAC1 directly interacts with TRPV4 in GC cells. However, VIP did not affect TRPV4 expression (Appendix Fig S8A and B) , and no interaction was observed between VPAC1 and TRPV4 channels (Appendix Fig S8C) . Since VPAC1 is coupled to PLCβ stimulation which produces diacylglycerol (DAG) that can activate TRPC channels (Leuner K et al, 2010; Storch U et al, 2017) , we examined whether 1-oleoyl-2-acetyl-sn-glycerol (OAG), a ] cyt increase, which was blocked by RN1734 ( Fig 5F) . In GC cells, the VIP-induced
] cyt rise was strongly reduced by the expression of DAG kinase β (DGKβ), an enzyme that decreases the intracellular DAG level by converting DAG to phosphatidic acid ( Fig 5G) , but augmented by the treatment of RHC80267, a DAG lipase inhibitor that causes accumulation of endogenous DAG ( Fig 5H) . Taken together, these results clearly indicate that VIP/VPAC1
activates TRPV4 channels via PLC generation of DAG.
VIP/VPAC1 promotes gastric cancer progression through TRPV4 -mediated Ca 2+ signaling pathways RN1734 markedly decreased VIP-induced migration (Appendix Fig S9A and B) and invasion of GC cells (Appendix Fig S9C) . Furthermore, TRPV4 knockdown significantly decreased VIPinduced migration and invasion ( Fig 6A) . Similarly, TRPV4 knockdown greatly reduced VIPinduced lung metastases ( Fig 6B) and peritoneal dissemination in mice ( Fig 6C) . Together, these results suggest that TRPV4 plays a critical role in VIP/VPAC1 promotion of GC invasion and metastases.
To identify the downstream signaling of TRPV4 activation induced by VPAC1 activation, we evaluated Ca
2+
-dependent activation of β-catenin, ERK1/2, and JNK, which have been suggested to be important for GC progression (Xiao G et al, 2015; Song W et al, 2014; Ma Y et al, 2016) .
We showed that VIP treatment increased phosphorylation of β-catenin, ERK1/2 and JNK in a time-dependent manner (Appendix Fig S10A) , which was significantly attenuated by VPAC1 knockdown (Appendix Fig S10B) , BAPTA-AM ( Fig 6D) or RN1734 ( Fig 6E) . To examine the roles of these signaling pathways in VIP-promoted GC progression, we knocked down ERK1/2, JNK and β-catenin, which parallelly led to significant decreases in both protein expression and VIP-induced migration and invasion of GC cells (Fig 6F and G) . Therefore, TRPV4/Ca 2+ -mediated β-catenin, ERK1/2, and JNK pathways play key roles in VIP/VPAC1-promoted GC progression.
VPAC1/TRPV4/Ca 2+ signaling enhances VIP expression and secretion in gastric cancer cells
Since serum VIP concentration was increased in patients with gastrointestinal cancers (Hejna M et al, 2001) , we examined whether GC cells could secrete VIP to produce an autocrine regulation during GC progression. Interestingly, we found that VIP could induce VIP mRNA expression in a time-dependent manner ( Fig 7A) , which was attenuated by the knockdown of VPAC1 ( Fig 7B) or TRPV4 (Fig 7C) , or BAPTA-AM (Fig 7D) , indicating that VIP induces VIP mRNA expression in GC cells through VPAC1/TRPV4/Ca 2+ signaling pathway. We also found that VIP protein secretion in culture medium was significantly inhibited by the knockdown of TRPV4, or by BAPTA-AM ( Fig 7E) . To further elucidate the underlying mechanisms, we tested cAMP-responsive element binding protein (CREB) and nuclear factor of activated T-cells (NFAT), two transcription factors known to be essential for Ca
2+
-mediated gene regulation (Yin Y et al, 2016; Hogan PG, 2017) . We found that the knockdown of CREB but not NFAT attenuated the VIP-induced increase in VIP expression (Fig 7F) . Similarly, serum VIP secretion was reduced by the knockdown of VPAC1 or TRPV4 in GC xenografts in vivo (Fig 7G) , and VIP expression in the tumor tissues of GC xenografts was also significantly decreased by the knockdown of VPAC1 or TRPV4 (Fig 7H and I) . Furthermore, the expression levels of VIP were positively correlated with those of VPAC1 in GC specimens (Fig 7J) , and serum VIP concentrations in GC patients were higher than those in normal individuals (Fig 7K) , which is consistent with previous studies (Hejna M et al, 2001) . VIP knockdown significantly inhibited GC invasion and metastasis, which were further reduced by knockdown of both VIP and VPAC1
(Appendix Fig S11) . More importantly, survival was improved in mice after VIP or VPAC1 knockdown (Appendix Fig S12) , which is consistent with the survival results of GC patients.
Taken together, these results reveal a positive feedback mechanism of VIP/VPAC1/TRPV4/Ca 2+ signaling via CREB to promote GC progression by enhancing VIP expression and secretion.
Discussion
Tumor metastasis is a complicated process with diverse mechanisms, and it could be promoted by the production of cytokines, chemokines, growth factors, neuropeptides and proteinases (Chen F et al, 2015) . In the present study, we identified that VIP and VPAC1 were extensively overexpressed in human primary GC tissues and cell lines, which were positively correlated with advanced clinical stage, lymphatic metastasis, and poor survival, suggesting VIP/VPAC1 played critical roles in regulating GC metastasis and progression. Mechanistically, VPAC1 activation promotes migration and invasion of GC cells through TRPV4 channel-dependent Ca 2+ entry, which in turn augments VIP expression and secretion to form a feedback regulation to worsen GC progression. Importantly, enhanced expressions of VPAC1 have potentially diagnostic and prognostic significance for gastric cancer. Taken together, these findings indicate that VPAC1 13 serves as an important regulator of GC metastasis and progression, which may be a novel candidate for gastric cancer diagnosis and therapy.
Previous studies showed that Ca 2+ signaling elicits many biological responses, and aberrant Ca 2+ signaling is involved in different pathogenesis (Berridge MJ et al, 2003; Galione A & Churchill GC, 2002) . VIP stimulation and VPAC1 activation are well recognized to trigger Ca 2+ signaling (Li D et al, 2013; Hagen BM et al, 2006) , but it remains totally unknown whether VIP-mediated Ca 2+ signaling plays a role in gastrointestinal malignancy. Here we demonstrated for the first time that inhibition of TRPV4-mediated Ca 2+ entry effectively inhibited VIP/VPAC1-stimulated GC progression. Previous studies showed that GPCR activation could promote DAG/PKC to stimulate activities of TRPV1 and TRPV4 channels (Woo DH et al, 2008) . Consistently, our results indicated that VIP activation of VPAC1 enhanced TRPV4 channels via PLC-induced DAG generation in GC cells. Since [Ca 2+ ] cyt rise is well known to activate ERK1/2, JNK and β-catenin in different cell types (Andrikopoulos P et al, 2015; Favia A et al, 2014; Thrasivoulou C et al, 2013) , we found that most of these downstream effecter kinases were also activated by TRPV4-mediated [Ca 2+ ] cyt rise in GC cells. Taken together, we identified a novel coupling of VPAC1 and TRPV4 channels and subsequent activation of Ca
2+
-dependent kinases, which may play a major role in GC progression.
It is worthy to note that serum VIP concentrations in GC patients were much higher compared to normal healthy subjects and that the expression levels of VIP were positively correlated not only to those of VPAC1 expression, but also to metastatic potentials and poor prognosis of GC patients. The serum VIP concentrations are usually increased in the patients with GI cancers (Hogan PG, 2017) , but the underlying mechanisms are still obscure. The much higher expression of VIP in GC tissues prompted us to test the hypothesis that GC cells might secrete VIP via an 14 autocrine regulatory mechanism to raise its serum levels. Indeed, we found that VPAC1 activation enhanced VIP expression in GC cells, which was significantly attenuated by Ca 2+ chelation, indicating a positive regulation of VIP gene transcription by Ca 2+ signaling in GC cells.
Previous studies showed that CREB was involved in Ca
-mediated activation of brain-derived neurotrophic factor gene promoters (Tabuchi A et al, 2002) . Similarly, VIP gene promoter contains a cAMP-responsive element (CRE) located 70 bps upstream of the transcription initiation site (Hahm SH et al, 1998) , which is supported by our observation that the knockdown of CREB attenuated VIP-induced expression of the neuropeptide itself. Therefore, it is most likely that VIP expression is enhanced by Ca 2+ signaling through promoting the binding of CREB to CRE of VIP gene. Furthermore, VIP-induced Ca 2+ entry through TRPV4 channels is also likely critical for the exocytosis (Schwarz EC et al, 2013) , which is consistent with the previous reports that activation of VPAC1 induced a transient membrane depolarization that might trigger Ca 2+ signaling to promote cytokine secretion (Tompkins JD et al, 2010; Liu F et al, 2015) . Therefore, the present study elucidates the detailed mechanism underlying the increase of serum VIP in the patients with GI cancer.
In conclusion, we have identified a novel molecular pathological mechanism in which VIP promotes GC progression through the VPAC1/TRPV4/Ca 2+ signaling cascade, which in turn activates VIP expression and secretion via CREB to worsen GC progression (Fig 7L) . Increased expressions of VIP/VPAC1 have potentially diagnostic and prognostic significance for gastric cancer, and targeted inhibition of VIP/VPAC1 expression and its downstream signaling may be a novel strategy for gastric cancer diagnosis and therapy.
Materials and Methods
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Ethics statement
Informed consent was obtained for all patients involved in this study. images of all tissue cores were acquired at the same time with a constant set of imaging parameters on the microscope and imaging software. The images were then subjected to optical density analysis by ImagePro Plus software. The intensity range selection was based on histograms, with the intensity (I), saturation (S), and maximum hue (H) set at a range in which most of the brown diaminobenzidine color could be quantified. After defining the AOI (area of interest), the mean optical density of the selected area [integrated optical density (IOD)/unit area] was determined by the software and used to represent the immunoreactivity of the candidate protein within the tumor tissue. The acquired score of the optical density was normalized and subjected to ImagePro Plus for analysis.
Quantitative real-time PCR
Total RNA was extracted by RNAiso plus (Takara, Japan). The RNA was reverse transcribed to cDNA using PrimeScript RT-polymerase (Takara, Japan). Quantitative PCR was performed using primers specific for VPAC1, VIP and TRPV4. The gene GAPDH was used as an internal control. All quantitative PCR assays were conducted using SYBR Premix EX Taq (Takara, Japan) and an ABI detection system (Applied Biosystems, Foster City, CA, USA). All reported results are average ratios of three independent experiments.
Western blotting
Cells and tissue samples were lysed with a lysis buffer and centrifuged at 12,000 g for 15 min to remove insoluble materials. The protein concentration was measured using a Bradford Protein Assay Kit (Beyotime, Beijing, China). The lysates were separated by SDS-PAGE (10%).
Resolved proteins were transferred onto a PVDF membrane (Millipore, Billerica, MA, USA).
Membranes were blocked in the blocking buffer, and then incubated with primary antibodies:
anti-VPAC1, anti-VIP, anti-TRPV4, anti-p-ERK1/2 (Cell Signaling Technology (CST), Beverly, MA, USA), anti-p-JNK (CST, MA, USA), anti-pSer552 (CST, MA, USA), anti-pSer675 (CST, MA, USA), anti-β-catenin (Abcam, Cambridge, MA, USA) and mouse monoclonal anti-GAPDH (Abcam, Cambridge, MA, USA). These were followed by incubation with appropriate secondary antibodies conjugated with horseradish peroxidase and detection using chemiluminescence (Millipore, Temecula, CA, USA).
Scratch Assay
Cells from each group were seeded into 24-well plates at a density that reached 80% confluence as a monolayer at 24 h. The monolayer was gently scraped in a straight line with a 10 μl pipette tip to create a "scratch". The scratch created was of a similar size in the different experimental conditions to minimize possible variations caused by the difference in the initial width. After 18 scratching, the well was gently washed with medium to remove the detached cells. After different treatments as described, images were acquired at 0 h and 24 h under a microscope. In each group, at least 3 parallel wells were utilized for testing.
Boyden Chamber Assay
The Boyden chamber assay was performed to evaluate the ability of cells to migrate, which makes use of a chamber composed of two medium filled compartments separated by a micro porous membrane (BD Biosciences, San Diego, CA, USA). The lower well contained medium with 5% (vol/vol) serum. Cells were placed in the upper chamber and treated with VIP or inhibitors, such as RN1734 or other treatments as described. Cells were allowed to migrate through the pores of the membrane into the lower compartment. After 24 h, cells that had migrated onto the lower surface were stained with crystal violet. The number of cells that had migrated to the lower side of the membrane was evaluated under a microscope (Olympus, Japan).
Triplicate experiments with triplicate samples were performed.
Cell invasion assay
Briefly was omitted from and 0.5 mM EGTA was added to PSS to prevent possible Ca 2+ contamination.
All inhibitors or treatments were applied as described.
Electrophysiological assessment of TRPV4 currents
Whole-cell voltage clamp recordings were made from cultured GES-1 and MKN-45 cells seeded on glass coverslips (~40% confluence) using an EPC10 amplifier (HEKA Elektronik MgCl 2 , 10 HEPES, 10 Glucose, pH 7.4 adjusted with NaOH, 310 mOsM. Cells were held at 0 mV. Voltage ramps from -100 to 100 mV in 500 ms were applied repetitively every 2 sec while the recorded cell was continuously perfused with ECS. VIP and RN1734 were applied at desired time periods through perfusion. All recordings were conducted at room temperature (~23°C).
Immunofluorescence staining
GC cells were grown on coverslips, fixed with 4% paraformaldehyde (w/v) for 30 min, and then permeabilized with 0.5% Triton X-100 in phosphate-buffered saline (PBS) and blocked with bovine serum albumin. The cells were incubated with primary rabbit anti-VIP or anti-TRPV4 (Millipore, Temecula, CA, USA) at 4 °C overnight. After careful washing with PBS, the cells were incubated with secondary antibodies conjugated to Cy3. Fluorescent images were observed and analyzed with a laser scanning confocal microscope (Olympus, Japan).
ELISA assay
VIP levels were determined by sandwich ELISA using human VIP ELISA Kit (Biocompare, South San Francisco, CA, USA) according to the manufacturer's instructions. Briefly, cells were treated as indicated, and 100 μl of the culture medium or 40 μl of serum were transferred into 21 microplate wells precoated with a monoclonal antibody specific for VIP, and incubated for 2 h at 37 °C. An enzyme-linked polyclonal antibody was then added to the wells and incubated for 1 h at 37 °C to sandwich the VIP ligand. After careful wash, a substrate solution was added and the intensity of the color was determined using an automicroplate reader (Thermo Scientific, Carlsbad, CA, USA). Each experiment was conducted twice and each sample point was assessed in triplicate.
In vivo metastasis assay
MKN45 cells, untransfected or transfected with the lentiviral vectors Lv-sh-NC, Lv-sh-VPAC1, Lv-sh-VIP, or Lv-sh-TRPV4 were used. For the in vivo lung metastasis assay, 1×10 6 transfected cells were suspended in 200 μl PBS for each mouse. The cells were injected into nude mice (five mice per group, five-week-old male BALB/c-nu/nu mice) through the tail vein. Then VIP or PBS was injected through tail vein once a day. After 12 weeks, the mice were sacrificed. Each lung was divided into five blocks, embed in paraffin, and the paraffin mass was cut into five sections, which were stained with hematoxylin and eosin. The metastatic nodules were observed under a microscope and calculated. For the peritoneal dissemination assay, MKN45 cells were transfected as indicated, and 1×10 6 transfected cells were injected into the abdominal cavity of nude mice (five mice per group, five-week-old male BALB/c-nu/nu mice). Then, VIP or PBS was injected into the abdominal cavity once a day. Six weeks later, the mice were killed, and the nodules were observed and counted.
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Statistical Analysis
Data are expressed as means ± SEM. A two-tailed Student's t-test or Mann-Whitney test was used to determine the differences between groups. The Kaplan-Meier curves were plotted to assess the effect of VIP/VPAC1 expression on survival, and survival curves were compared using the log-rank test. The  2 test was used to test possible associations between VIP/VPAC1 expression and clinicopathological factors. The correlation coefficients were determined using
Pearson's rank correlation test. Multivariable Cox proportional hazards regression models were used to assess the prognostic significance of VIP/VPAC1 expression. IBM SPSS Statistics V.22
software (IBM, Armonk, New York, USA) was used for statistical analysis, and the graphs were generated using GraphPad Prism 6.0 (Graphpad Software Inc, CA, USA). 
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The Paper Explained Problem
Gastric cancer is the second leading cause of cancer-related death worldwide. Although the diagnosis and treatment have been improved over the past decades, the prognosis remains poor due to its early invasion and metastasis. Tumor invasion and metastasis is a complex biological process, and growing evidence show that the interaction between cancer cells and the surrounding microenvironment is critical for tumor metastasis. However, the molecular mechanisms of the invasion and metastasis of gastric cancer are still poorly understood.
Results
We revealed that VPAC1 was overexpressed in GC tissues and was significantly associated with the depth of invasion, advanced TNM stage and distant metastasis. High expression of VPAC1 in GC was an independent prognostic predictor and the GC patients with high VPAC1 expression usually had poor survival. Mechanistically, VPAC1 activation by VIP markedly induced TRPV4-mediated Ca 2+ entry and GC progression. VPAC1/TRPV4/Ca 2+ signaling in turn enhanced the expression and secretion of VIP in GC cells, enforcing a positive feedback regulation in GC progression. Our findings suggest that VPAC1 has potentially diagnostic and prognostic significance for GC, and targeting VPAC1 and its downstream signaling could attenuate GC metastasis.
Impact
Our results highlight the importance of VPAC1/TRPV4/Ca 2+ signaling in gastric cancer development, and provide a novel strategy for developing new drugs targeting this pathway for gastric cancer treatment. 
